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Abstract
Cystic Fibrosis (CF) is the most common monogenic disease among people of Western
European descent and caused by mutations in the CFTR gene. However, the disease
severity is immensely variable even among patients with similar CFTR mutations due to the
possible effect of ‘modifier genes’. To identify genetic modifiers, we applied RNA-seq based
transcriptomic analyses in CF patients with a mild and severe lung phenotype. Global gene
expression and enrichment analyses revealed that genes of the type I interferon response
and ribosomal stalk proteins are potential modifiers of CF related lung dysfunction. The
results provide a new set of CF modifier genes with possible implications as new therapeutic
targets for the treatment of CF.
Introduction
Cystic fibrosis (CF) is the most common life-threatening genetic disease among people of
Western European descent. The disease is caused by a mutation in the underlying disease-
conferring gene, Cystic Fibrosis Transmembrane and Conductance Regulator (CFTR) that
encodes a chloride channel. CFTR mutations result in disrupted chloride transport in the epi-
thelial cells of various organs including lung, intestine, pancreas, and testes [1]. More than
2000 CFTR genetic variants have been reported and categorized into six classes, as these muta-
tions were observed to exhibit diverse effects on the production of CFTR protein, its traffick-
ing, its function, and its stability at the epithelial cell membrane [1, 2]. The most prevalent
mutation in CF is the lack of a phenylalanine residue at position 508 (also known as F508del),
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which results in a misfolded CFTR protein with reduced transmembrane conductance of chlo-
ride ions [3]. Due to the trafficking defect, the F508del mutation prevents the CFTR protein
reaching the apical membrane of epithelial cells and also interrupts the normal movement of
chloride ions by disrupting CFTR channel gating [4].
Chronic progressive lung disease is the primary reason for morbidity and mortality in CF.
However, the disease severity is immensely variable even among patients with similar CFTR
mutations. For instance, CF patients with a homozygous F508del mutation showed varying
phenotypic heterogeneity in terms of lung function that is measured by forced expiratory vol-
ume in 1 second (FEV1) [5]. It has been observed that CFTR genotypes per se do not corrobo-
rate with the pulmonary phenotype in unrelated CF patients [6]. However, twin and sibling
studies clarified that the modifier genes and their genetics contributed substantially to diver-
gent outcomes observed in CF lung disease [7, 8]. As CF is a multi-organ disease, the contribu-
tion of modifier genes towards disease severity was relatively higher when compared to non-
genetic modifiers in specific organs [9].
Modifier genes are a vital part of human genetics and it is argued that they are responsible
for the diverse phenotype observed with various diseases, more precisely in CF [10, 11]. Several
CF related modifier genes have been reported through genome-wide association studies
(GWAS), hypothesis-driven candidate gene studies, and microarray based transcriptomic
analyses [5, 9, 12–15]. Unlike GWAS and candidate gene studies, transcriptomic analyses pro-
vide information on both genetic modifiers and non-genetic modifiers such as infections from
the environment. The host immune system responds to these infections by activating immune
genes, and these gene transcripts can be measured by transcriptomic approaches. Though
microarray-based transcriptomic analyses could identify some modifier genes, the technology
is limited to known transcripts [12, 16, 17]. However, global gene expression analysis using
RNA-seq provides several advantages over microarray including the detection of a higher
number of differentially expressed genes and the detection of novel transcripts [18]. Therefore,
in the present study we performed a transcriptomic analysis using RNA-seq on CF patients
with an identical genotype (homozygous F508del), but with mild and severe lung dysfunction
determined by FEV1 measurements.
Materials and methods
Patient samples
A total of 32 F508del homozygous CF patients were recruited for the study from the University
Childrens’ Hospital, Tuebingen, Germany and the Division of Paediatric Respiratory Medi-
cine, University of Bern, Switzerland. All blood samples were collected in PaxGene blood vacu-
tainer tubes to ensure RNA quality and significantly reduce RNA degradation. Participants
were classified into severe CF patients (n = 16) and mild CF patients (n = 16) based on their
FEV1 values, which is a standard to quantify the clinical phenotype of CF. The detailed clinical
characteristics of the enrolled patients are described in Table 1. For statistical analyses of clini-
cal parameters, data were analyzed using the Mann-Whitney U test and are presented as
means and SDs, unless stated otherwise. Ethical approval was obtained from the Institutional
review board, Children’s University Hospital Tuebingen, Germany. Informed written consent
was obtained from all participants; for those who were children, consent was obtained from
respective parents or guardians.
RNA library preparation
Total RNA was isolated with PAXgene tubes using a Qiacube roboter with standard proto-
cols (www.qiagen.com). Excess globin mRNA was removed with GLOBINclearTM kit and
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sequencing libraries were prepared with the TruSeqTM Total RNA Sample Prep Kit following
the manufacturer’s instructions (www.illumina.com). Each sequencing library was tagged with
a 6 nucleotide long barcode that identifies from which sample a sequence was derived. After
size selection, all sequencing libraries were quantified on a Qubit1 fluorometer and equimo-
lar amounts of 16 libraries were combined to generate two sequencing pools. These were
loaded onto 8 lanes of an Illumina GAIIx single-read flow cell and two MiSeq flow cells.
Bound molecules were clonally amplified on a cBot instrument. Subsequently, the first 50
nucleotides from each fragment were sequenced followed by a seven nucleotide sequencing
run to decipher the barcode sequence in the adapter (www.illumina.com).
RNA-seq data analysis
The quality of raw sequenced reads was assessed using the fastqc quality control tool and high-
quality reads were aligned against the Homo sapiens reference genome (hg19) using the STAR
RNA-seq alignment tool [19]. The STAR aligners automatically detect and remove adaptor
sequences from the sequence reads before alignment. Next, we calculated the total number of
mapped reads and the number of uniquely mapped reads for each sample. As an additional
layer of quality control, we discarded samples with low mapped read count and samples with
a small percentage of uniquely mapped reads. For samples that pass the additional quality
check, we estimated the gene expression level as CPM (count per million mapped reads) using
HTSeq [20]. We used EdgeR R package to identify differentially expressed genes (DEGs)
between mild CF and severe CF [21]. RNA-Seq reads are available in NCBI-Sequence Read
Archive (SRA) database, under accession number SRP111640. Samples in each CF group were
treated as biological replicates and only genes that pass the significance cut-off were treated
as DEGs. In this study, we used log fold-change in expression less than -0.5 or greater than
0.5 and P-value (FDR corrected P-value) less than 0.05 as the significance cut-off to identify
DEGs. In order to functionally categorize DEGs, we tested enrichment of Gene Ontology
(GO) terms among DEGs using Amino.2 (www.amigo.geneontology.org). Additionally, we
also analyzed DEGs for the over-representation of KEGG pathways (http://www.genome.jp/
kegg/pathway.html). Motif activity response analysis (MARA) was performed to predict the
global regulatory interaction of RNA-seq data using ISMARA online tool (www.ismara.
unibas.ch). MARA predicts transcription factor (TF) binding sites with a specific algorithm
and calculates the influence of specific TF in terms of gene expression in a given sample.
Mann-Whitney U rank sum tests were applied to analyze differences in motif activity between
the study groups. All the major DEGs were checked for their association with CF using Open
target Platform (www.targetvalidation.org).
Table 1. Clinical characteristics of the mild CF and severe CF samples.
Clinical Parameters Mild CF patients Severe CF patients P value
Number (n) 16 16 Not Significant
Age, mean (SD) 25 (12) 21 (9) Not Significant
Male:Female 10:6 8:8 Not Significant
CFTR Mutation F508del/ F508del F508del/F508del Not Significant
FEV1 (% predicted), mean (SD) 92 (16) 36 (10) < 0.0001***
Infections PSA, SA, CA, SM PSA, SA, CA, SM, AF Not Significant
*** Mann-Whitney U test.
PSA, Pseudomonas aeruginosa; SA, Staphylococcus aureus; CA, Candida albicans; SM, Stenotrophomonas maltophilia; AF, Aspergillus fumigatus.
https://doi.org/10.1371/journal.pone.0183526.t001
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qPCR validation
qRT-PCR validation was performed for 16 of the DEGs utilizing the same samples utilized for
RNA-seq as a technical reproducibility operating different platforms. Primers were designed
with the Primer3 online tool (www.primer3.ut.ee) Primers, amplicon details, and cycling con-
ditions are listed in Table 2. cDNA was synthesized using iScript (www.biorad.com), followed
by qRT-PCR using Power SYBR green, and samples were run in triplicate on a ViiA7 Real-
Time PCR System (www.lifetechnologies.com). The relative expression levels of selected
DEGs were normalized to the 18S rRNA. Differences in mRNA expression between mild CF
and severe CF were analyzed by pair-wise fixed reallocation randomization tests with REST
2009 software [22]. The severe CF patients group was used as a control group and statistical
Table 2. Primer details and PCR cycling conditions for the qPCR validation.
Gene Primer sequences (5’-3’) Amplicon Size (bp) Annealing Temperature (˚C)
HERC5 F: CCAGCTTGCTTGTCCAACAG 157 58
R: CGGCCAGTAAACCCTCTTCT
IFIT1 F: TGGACCCTGAAAACCCTGAA 243 54
R: TCTGTGAGGACATGTTGGCT
IFIT2 F: GCGAAACAACTGCTCCATCT 205 55
F: CCAAGACATGCAAAGCCTCA
RSAD2 F: AAGAGGAGGAAGAGGACCCT 250 55
R: CAGAACCTCACCAACTTGCC
IFI44L F: GAGCAACTGGTGTGTCGTTT 213 56
F: CCTATTTCTGTGCTCTCTGGC
GOS2 F: GGAATGGAGAGACAGAGGGG 239 59
R: AGTGCAAAATGGTAGACGCA
CXCL10 F: TGGATGTTCTGACCCTGCTT 201 56
R: AAAGAATTTGGGCCCCTTGG
FOSB F: TCTGTCTTCGGTGGACTCCTTC 209 57
R: GCAAACCGTAGATGCTCAGGG
OAS3 F: GCTTCACAGAGCTACAACGG 167 58
R: CTCCCAGGCATACACAGTCA
IFI6 F: AGCAGCGTCGTCATAGGTAA 213 56
R: TGCACTCTAGCCTGGACAAT
MX1 F: CATCCAGCCACCATTCCAAG 168 57
R: AGAATCGCTTGAACCTGGGA
EGR1 F: AGCTGGAGGAGATGATGCTG 257 54
R: CCAGCACCTTCTCGTTGTTC
IL8 F: TCTTGGCAGCCTTCCTGATT 211 56
R: TCCAGACAGAGCTCTCTTCCATC
LOC644172 F: CCGACGTCCATTTCTCCAAG 184 58
R: TCATCCACTTCCAGCTCAGG
ZFN683 F: AGCCTTGCCTTACCCGCTGAAA 129 60
R: AATGGACGCTCTCCACTGTGCA
EPB41L4B F: ACCCACTTCCTTGACAGAGT 233 55
R: CGCAAGTTAGCAGCACCAAT
18s rRNA F: GTAACCCGTTGAACCCCATT 151 54
R: CCATCCAATCGGTAGTAGCG
https://doi.org/10.1371/journal.pone.0183526.t002
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significance was determined using randomization tests. In addition, the expression of each
gene was determined for every single patient using the 2-ΔΔCt method and Mann-Whitney U
tests were applied for separate gene analyses between study groups. The level of significance
was set to a P-value of<0.05.
Results
We investigated the transcriptomic profile of peripheral blood leukocytes from mild and
severe CF patients using RNA-sequencing. No differences were evident for important clinical
parameters between the investigated groups, except for the FEV1 status (P<0.0001; Table 1).
After the quality check for RNA-seq data, three samples were removed from downstream anal-
yses due to the low number of total reads and lower mapping rate (S1 Fig). In total, 12,778
genes with at least ten reads per sample were included in the final analysis stage. The principal
component analysis (PCA) of the final data revealed that the differences in the expression pro-
files of the two investigated groups were relatively small (S2 Fig).
Differentially expressed genes (DEGs) between mild CF and severe CF
Differential expression analysis showed that 88 genes were differentially expressed between
mild and severe CF group of patients, among which 74 genes (84%) had higher expression lev-
els in mild CF patients and 14 (16%) genes had higher expression levels in individuals with
severe CF. The results from this analysis with respective expression levels and adjusted P-val-
ues can be found in S1 Table. We compared DEGs between mild and severe CF patients and
the heat-map of the selected DEGs revealed two distinct clusters for the investigated groups
(Fig 1A). Global gene level expression analysis between the groups (mild CF vs. severe CF) is
shown in volcano plots (Fig 1B) with respective gene name, expression level and accuracy of
the detection using RNA-seq. EGR1, SFRP1, RSAD2, and FOSB are the major DEGs that were
Fig 1. RNA-seq analyses of Mild CF and severe CF patients. A) Heat-map of differentially expressed genes. Each column represents a separate
patient, and each horizontal line represents a separate gene. Dendrogram of clustered samples and genes, in which mild CF and severe CF samples
cluster with respect to their expression similarity. Expression profiles are measured by counts per million reads (CPM- model). B) Volcano plot of RNA-seq
data, in which the -Log10 of the false discovery rate is plotted against Log2 fold change.
https://doi.org/10.1371/journal.pone.0183526.g001
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significantly overexpressed (>3.5) in the mild CF group in comparison with the severe CF
group. Increased expression of EGR1 was found to be significantly associated with mild lung
disease (fold change = 4.5; FDR P = 3.1x10-6). Concordantly, other EGR family genes, EGR2
(fold change = 2.4; FDR P = 0.04) and EGR3 (fold change = 2.6; FDR P = 0.02) showed higher
level of expression in the mild CF group. Similarly, EPB41L4B, LOC644172,C4BPA, and
ZNF683 are the major DEGs that were significantly overexpressed (>1.5) in the severe CF
group (S1 Table). Among these genes, ZNF683 exhibited better association with the severe
form of CF lung disease (fold change = 1.5; FDR P = 0.0002).
qPCR validation of RNA-seq data
We validated RNA-seq findings for 16 DEGs by qPCR using the same samples and observed
high concordant results between RNA-seq and qPCR (94%; 15 out of 16 DEGs were verified;
Fig 2A). The comparison of DEG expression levels between RNA seq versus qPCR revealed
better correlation (Spearman’s rho, ρ = 0.53, P = 0.04; Fig 2B). Thus, these 15 genes had similar
mRNA levels, as RNA-Seq and qRT-PCR data were comparable. Furthermore, significant dif-
ference in expression levels was observed in qPCR results for the mild CF group with following
genes, IFIT2 (fold change = 3.2, P<0.001), MX1 (fold change = 3.2, P<0.05) and ZFN683 (fold
change = -2.1, P<0.05). No significant difference was achieved for EGR1 as many samples of
the severe CF group failed in amplification (data not shown). IL-8 was the only DEG that
could not be verified by qPCR. Since IL-8 is a very important proinflammatory cytokine in CF
settings, we further dissected the IL-8 data for both platforms. RNA-seq data showed that IL-8
was overexpressed in the mild CF group (Figs 2A and 3B). Conversely IL-8 was significantly
overexpressed in the severe CF group according to qPCR analysis (P = 0.01; Fig 3A).
Enrichment and MARA analysis
To understand the biological processes that could be modified differently between the mild CF
and the severe CF group, we performed a GO enrichment analysis for DEGs that are upregu-
lated in mild and severe CF. In case of the mild CF group, genes that belongs to type I
Fig 2. qPCR validation of RNA-seq findings. A) Expression profile of RNA-seq data and qPCR data for selected genes were compared using the
same samples. Severe CF samples were used as control group and the expression level set to 1 or -1. Expression was normalized using 18s as a
reference gene. Results represent mean values and are expressed as Log2 values of the fold change. Significant difference observed in qPCR results
between mild CF and severe CF patients (**P value < 0.05; ***P value < 0.001). The level of significance was set to a P-value of < 0.0001 for RNA-seq
data. B) Correlation analysis of RNA-seq and qPCR. (Log2 values of the fold change; Spearman’s rho, ρ = 0.53, P value = 0.04).
https://doi.org/10.1371/journal.pone.0183526.g002
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interferon response were selectively enriched (38%, P = 1.45E-09; Fig 4A, S2 Table). A total of
ten genes involved in this pathway showed elevated expression in the mild CF group (EGR1,
MX1, IFIT1, IFIT2, IFIT3, OAS3, OASL, IFI6, ISG15, and RSAD2). In addition, the pathways of
the anti-viral response and the immune effector process showed significant enrichment (S2
Table). Enrichment analysis identified three ribosomal stalk protein genes RPL31, RPL34, and
RPS24were enriched in the pathway of protein targeting to the endoplasmic reticulum (ER).
No specific pathway was enriched for the fourteen-upregulated genes of the severe CF group.
To explore the contribution of specific TFs and regulatory networks of DEGs we implemented
MARA analysis to our RNA-seq data. Our data revealed that IRF1, IRF2, IRF8,and STAT2
Fig 3. IL-8 expression by qPCR and RNA seq. A) Dot-plot shows the expression of IL-8 in severe and mild CF patients. Expression was normalized
using 18s as a reference gene. Results represent mean values and are expressed as Log2 values of the fold change. B) Using the same data of Fig 2A
for IL-8 to understand different results between platforms.
https://doi.org/10.1371/journal.pone.0183526.g003
Fig 4. Functional enrichment analysis of RNA-seq data. A) Representative Gene Ontology (GO) terms enrichment among differentially
expressed genes for biological processes. Genes involved in Type I interferon response, and ribosomal proteins responsible for endoplasmic
reticulum transport and protein synthesis were over represented. B) ISMARA analysis predicts significant difference in IRF1,2,8 and STAT2 activity
between mild CF and severe CF patients (*P value < 0.05).
https://doi.org/10.1371/journal.pone.0183526.g004
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transcription factor activity were significantly increased in the mild CF group (mean activation
z-score for mild CF 2.5, mean activation z-score for severe CF -2.3; P< 0.05; Fig 4B) with ele-
vated transcript levels of their regulated genes. Top target genes (Target score>10) for these
TFs belong to the type I interferon response pathway. The highest score (Target score >25)
was observed for the following genes: RSAD2, IFI44L, IFIT1, ISG15, IFIT3, OAS3, HERC5, and
IFI44 (S1 File). Both our enrichment and pathway analysis were consistent in identifying the
possible contribution of the type I interferon response in the mild CF phenotype. The network
analysis of IRF1,2,8 and STAT2 transcription factors showed closer interactions of the above
mentioned genes (S3 Fig) and other related genes in the type I interferon response.
Discussion
CF patients with identical inherited mutations in the CFTR locus exhibit substantial variation
in disease severity and lung function. The phenotypic heterogeneity of CF is majorly affected
by modifier genes [23]. Though several approaches are utilized to identify possible modifier
genes of CF, here we used a transcriptomics approach for this purpose [11]. A previous study
by Wright et al., attempted to identify modifier genes between mild and severe CF patients in
their nasal respiratory epithelial cells by a transcriptomics approach using microarray technol-
ogy. However global gene expression analysis using RNA-seq has many advantages over
microarray [24]. Therefore, in this study we primarily used RNA-seq technology to identify
modifier gene(s) of mild and severe lung phenotype in CF patients homozygous for the
F508del mutation. Primarily, we assessed whether our transcriptomics results from peripheral
blood leukocytes were comparable to native cells of the respiratory system (nasal, tracheal, and
bronchial epithelial cells) to avoid possible difference in these cell types. We compared our
data with six different studies and observed similar expression patterns for genes including
CXCL10, GOS2, PTGS2, IFIT1, IFIT3, and ISG15 [12, 16, 17, 25–27]. Thus, upregulated gene
profiles are relatively similar between blood leukocytes and native respiratory cells in CF. Like-
wise, both RNA-seq and microarray platforms resulted in common upregulated genes. Our
data suggest that the blood cell transcriptome can be used as a surrogate for both upper and
lower airway respiratory cells in CF. In addition, our RNA-seq data were validated using qPCR
with the same samples and resulted in a high coherence score (94%).
The differences in the expression profiles of the two investigated groups are relatively small
as they resulted in only 88 DEGs. However, we observed striking differences for these genes
between the mild and severe pulmonary phenotype of CF. Seventy four genes exhibited higher
expression in patients with mild CF lung disease compared with severe CF lung disease. A
total of 14 genes showed a significant upregulation in individuals with severe CF compared
with those with mild CF. Interestingly, enrichment analysis revealed that genes involved in the
type I interferon response and the defense response to viral infections were highly enriched in
the mild CF group. Though previous studies reported the association of type I interferon genes
(IFIT1, IFIT3, and ISG15) with CF [12], the present study confirms the role of the type I IFN
pathway in modifying CF. A very recent study using a systems biology approach identified a
type I interferon gene IFI16, as a major CF modifier gene that alters lung function [28]. The
type I IFNs are well-known for anti-viral response, and viral infections are potential contribu-
tors for a decline in lung function in CF patients [29]. Therefore, we carefully considered the
influence of viral infections with the observed expression profile. However, all our study par-
ticipants did not exhibit symptoms of cold or upper respiratory viral infections during blood
sampling. Therefore, we deemed that the contribution of viral infections to the observed DEGs
between mild and severe CF patients is less likely. However, increasing evidences suggest that
Type I IFN signaling pathway is involved in host defense against other pathogens including
Transcriptomics based identification of CF modifier genes
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bacteria, parasite and fungi [30]. For example, the type I interferon gene expression and their
polymorphisms were prominently associated with susceptibility to systemic candidiasis [31].
Notably, earlier studies confirmed that the type I interferon signaling was activated by Pseudo-
monas aeruginosa in normal lung epithelial cells but was abrogated in CF epithelial cells [32].
P. aeruginosa is a well-known pathogen in CF patients that has been directly associated with
decline in pulmonary function [33]. Of note, our study patients in both groups had fungal and
bacterial infections without significant differences in their distribution between groups. There-
fore, it is rational to hypothesize that due to the enhanced Type I IFN signaling, mild CF indi-
viduals kept their infections and lung function decline in control. This hypothesis can be
further supported by the anti-bacterial effect of the type I IFN response in lung epithelium and
the respiratory tract [34, 35]. The effect of another interferon related gene, IFRD1, in modify-
ing the pathogenesis of CF is well studied by others and us [15, 36]. Together, our findings sup-
port the contribution of IFN, specifically, the type I IFN response in modifying lung function
associated with CF.
Among the upregulated genes of the type I IFN response, EGR1 was a prominent gene that
shows higher expression in mild CF patients. A previous transcriptomic study had identified
that EGR1 was downregulated in P. aeruginosa infected CF bronchial epithelial cells [37].
Besides, EGR1 was observed to be upregulated in A. fumigatus and Toxoplasma gondii infected
cells [38], which signifies its significance during infections. Interestingly, we found that two
other EGR family members, EGR2 and EGR3, were also upregulated in the mild CF group.
EGRs are a family of DNA-binding zinc-finger proteins and function as transcriptional regula-
tors. In addition, EGR proteins were found to closely interact with other type I IFN genes
including Mx1, HERC5, RSAD, and others. Thereby, the role of EGRs as potential modifier
genes in CF lung disease warrants future research. Other potential modifier genes in type I
IFN signaling are Mx1 and IFIT2, as they play a dominant role against P. aeruginosa and their
expression also was verified by qPCR [35]. MARA analysis resulted in higher transcriptional
activity of IRF1,2,8 and STAT2 TF in mild CF patients and they are responsible for the higher
expression of Type I IFN genes. Enrichment analysis identified three ribosomal stalk proteins
RPL31, RPL34 and RPS24, that were highly expressed in individuals with mild CF. These pro-
teins were observed to be involved in protein trafficking to the ER and golgi transport. The rel-
evance of ribosomal stalk proteins in CF is well documented. Earlier study in primary human
bronchial epithelial cells with a homozygous F508del mutation showed that silencing of RPL12
was rescued by CFTR ion channel activity [39]. In addition, another ribosomal stalk protein
RPL27 was reported as chloride-dependent gene, which expression is related to the function of
the CFTR channel [40]. As the F508del mutation is related to protein trafficking and early deg-
radation in ER, these ribosomal stalk proteins are attractive for further research.
The CF lung environment is dominated by neutrophils and elevated levels of the proinflam-
matory chemokine, IL-8 [41]. A recent study presented a genetic association of IL-8 polymor-
phisms with FEV1 status of CF patients [42]. In our study, we observed increased expression of
IL-8 transcripts in individuals with mild CF. However, this observation could not be verified
by qPCR as more IL-8 expression was found in the severe CF group. A similar results was
observed in nasal epithelia cells between mild and severe CF and argued that IL-8 is not pre-
dictably associated with severity of the disease [17]. However, as we noted a contradicting
result between RNA-seq and qPCR, further validation with independent samples seems essen-
tial to explore the role of IL-8 in CF lung function variability. GWAS meta-analysis study with
a high sample number (n = 6,365) revealed the strong association of five genomic regions to
CF lung disease severity [13]. We examined whether any of the observed DEG shares the speci-
fied genomic location. Remarkably, we found that chromosomal mapping has assigned the
HCG27 gene to position 6p21.33, which is very close to the reported HLA-DRA locus at
Transcriptomics based identification of CF modifier genes
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6p21.32. Although HCG27 is reported to be a pseudo-gene, we observed a significant differ-
ence in expression levels between mild and severe CF individuals and the region including
HCG27 is also a major susceptibility loci for psoriasis [43]. Nevertheless, our present study
using a RNA-seq based transcriptomics approach was able to locate reported susceptibility loci
and thereby replicate the larger GWAS study. Although other genes described earlier do not
exactly match those identified in our study, they belong to the same biological families. For
example, ATP12A was reported to be responsible for airway acidification in CF, and we identi-
fied ATP6V1G1, a gene of the same family, in our study [44].
Collectively, our comparative transcriptomic analysis between mild and severe CF lung dis-
ease provided new insights into CF pulmonary decline. The global gene expression analyses
identified that genes of the type I interferon response and ribosomal stalk proteins and
revealed potential CF modifier genes. Our findings have the potential for picking new thera-
peutic targets from from this list of genes for treatment of cystic fibrosis.
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S1 Fig. Quality control of RNA-seq data. Absolute (A) and relative (B) number of reads
mapped to hg19.
(TIFF)
S2 Fig. Principal component analysis of mild and severe CF patients. PCA of the filtered
CPM counts data to assess the differences in the expression profiles of the two investigated
groups. Each point represents one sample; the closer two points are the more similar are the
expression profiles. CF manifestation is color-coded.
(TIFF)
S3 Fig. Network analysis of RNA-seq data. Network of MARA analysis predicts the possible
interaction of IRF1,2,8 and STAT2 target genes.
(TIFF)
S1 Table. List of DEGs in mild and severe CF patients. The results of differential expression
analysis between mild and severe CF group. The respective expression levels given as a fold
change and CPM with corrected P-Values.
(PDF)
S2 Table. GO Enrichement analysis of RNA-seq data. The results of GO enrichement analy-
sis for DEGs that are upregulated in mild and severe CF. Values of fold enrichment of speci-
fifed pathways with with corrected P-values were stated.
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S1 File. MARA analysis of RNA-seq data. The complete raw data of MARA analysis that pre-
dicted the IRF1,2,8 and STAT2 activity in RNA-seq.
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